Article
Effectiveness of GenoType MTBDRsl in excluding TB drug resistance in a clinical trial.
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease - 1 Oct 2021
Ejo M, Van Deun A, Nunn A, Meredith S, Ahmed S, Dalai D, Tumenbayar O, Tsogt B, Dat P T, Ha D T M, Hang P T, Kokebu D, Teferi M, Mebrahtu T, Ngubane N, Moodliar R, Duckworth L, Conradie F, Enduwamahoro E, Keysers J, De Rijk P, Mulders W, Diro E, Rigouts L, de Jong B C, Torrea G
Abstract excerpt
OBJECTIVES: To assess the performance of the GenoType MTBDRsl v1, a line-probe assay (LPA), to exclude baseline resistance to fluoroquinolones (FQs) and second-line injectables (SLIs) in the Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB 1 (STREAM 1) trial.METHODS: Direct sputum MTBDRsl results in the site laboratories were compared to indirect phenotypic drug susceptibility...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.